Taken together, our data support that HMGA2 may serve as both a potential diagnostic marker and therapeutic target in TC and suggest that HMGA2 inhibition offers promising perspectives for thyroid cancer treatment. This evidence concerns the gene HMGA2 and thyroid gland carcinoma.